We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Prof. Sibson together with her co-applicants Prof. Anthony, Dr Campbell and Prof. Middleton have now been awarded a second MRC DPFS grant, for £3.3 million, to acquire further preclinical data to support the case for clinical translation, to develop the mutTNF production for human use and to undertake pre-clinical toxicology.
Figure caption: Histology and magnetic resonance images from a mouse with breast cancer brain metastases, injected intravenously 2 hours previously with a TNFR1-selective mutant TNF protein. (A) Cresyl violet stained brain section showing location of a micrometastasis (boxed region and inset). (B) Adjacent brain section stained with Hanker-Yates demonstrates HRP extravasation (brown staining) and, hence, BBB breakdown selectively at the site of metastasis. (C) Post-contrast (gadolinium-DTPA) image from the same mouse showing extravasation of contrast at the metastatic site (hyperintensity) confirming local BBB breakdown. Note, the BBB remains intact in the rest of the brain.
